Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial.

Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G

Journal of clinical oncology : official journal of the American Society of Clinical Oncology1 Jan 1995Cited by 116 (Europe PMC)

PMID7799029DOI10.1200/jco.1995.13.1.26PepBankPUB-07799029

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialSafety outcome
In patients with advanced gastric cancer, no glutathione patients had clinical neuropathy at week 9, versus 16 placebo patients.
In plain wordsIn patients with advanced gastric cancer, neuropathy occurred less often with glutathione than placebo at week 9.
Peptide
Glutathione
Outcome
DecreaseClinical neuropathy at week 9
Study
n = 50
Comparator
Placebo with cisplatin-based chemotherapy
Outcome group
Adverse events · Nervous system and cognition
Studied dose
1.5 g/m2 before CDDP and 600 mg on days 2 to 5 · infusion and intramuscular injection · 9 weeksAs given in this study (human).
Measurements
Patients with clinically evident neuropathy
16 patients
Placebo arm at week 9
Source sentences
Summary
At the 9th week, no patients showed clinically evident neuropathy in the GSH arm, whereas 16 patients in the placebo arm did.
3 context sentences(design, population, supporting numbers)
Summary · context
Fifty patients with advanced gastric cancer treated with a weekly CDDP-based regimen were included in this study.
Summary · context
In patients randomized to receive GSH, GSH was given at a dose of 1.5 g/m2 in 100 mL of normal saline solution over a 15-minute period immediately before CDDP administration,
Summary · context
and at a dose of 600 mg by intramuscular injection on days 2 to 5.
Report a problemFND-0779902901
02HumanRandomized controlled trialSafety outcome
In patients with advanced gastric cancer, sensory nerve conduction decreased significantly with placebo but not glutathione, particularly potential amplitude.
In plain wordsIn patients with advanced gastric cancer, nerve conduction decreased significantly with placebo but not glutathione.
Peptide
Glutathione
Outcome
No significant changeSensory nerve conduction
Study
n = 50
Comparator
Placebo with cisplatin-based chemotherapy
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
1.5 g/m2 before CDDP and 600 mg on days 2 to 5 · infusion and intramuscular injectionAs given in this study (human).
Source sentences
Summary
the neurophisiologic investigations, based on the evaluation of the median, ulnar, and sural sensory nerve conduction, showed a statistically significant reduction of these values in the placebo arm but not in the GSH arm, above all considering potential amplitude.
3 context sentences(design, population, supporting numbers)
Summary · context
Fifty patients with advanced gastric cancer treated with a weekly CDDP-based regimen were included in this study.
Summary · context
In patients randomized to receive GSH, GSH was given at a dose of 1.5 g/m2 in 100 mL of normal saline solution over a 15-minute period immediately before CDDP administration,
Summary · context
and at a dose of 600 mg by intramuscular injection on days 2 to 5.
Report a problemFND-0779902903
03HumanRandomized controlled trialSafety outcome
In patients with advanced gastric cancer, glutathione reduced hemotransfusion requirements to 32 versus 62 with placebo.
In plain wordsIn patients with advanced gastric cancer, glutathione reduced transfusion requirements compared with placebo.
Peptide
Glutathione
Outcome
DecreaseHemotransfusion requirements
Study
n = 50
Comparator
Placebo with cisplatin-based chemotherapy
Outcome group
Adverse events · Whole body
Studied dose
1.5 g/m2 before CDDP and 600 mg on days 2 to 5 · infusion and intramuscular injectionAs given in this study (human).
Measurements
Hemotransfusion requirements
32 hemotransfusions
GSH arm
Hemotransfusion requirements
62 hemotransfusions
Placebo arm
Source sentences
Summary
In this trial, GSH also reduced hemotransfusion requirements (32 v 62 hemotransfusions) and treatment delay (55 v 94 weeks).
3 context sentences(design, population, supporting numbers)
Summary · context
Fifty patients with advanced gastric cancer treated with a weekly CDDP-based regimen were included in this study.
Summary · context
In patients randomized to receive GSH, GSH was given at a dose of 1.5 g/m2 in 100 mL of normal saline solution over a 15-minute period immediately before CDDP administration,
Summary · context
and at a dose of 600 mg by intramuscular injection on days 2 to 5.
Report a problemFND-0779902904
04HumanRandomized controlled trialEfficacy outcome
In patients with advanced gastric cancer, glutathione reduced treatment delay to 55 versus 94 weeks with placebo.
In plain wordsIn patients with advanced gastric cancer, glutathione reduced treatment delays compared with placebo.
Peptide
Glutathione
Outcome
DecreaseTreatment delay
Study
n = 50
Comparator
Placebo with cisplatin-based chemotherapy
Outcome group
Treatment adherence and retention · Cancer
Studied dose
1.5 g/m2 before CDDP and 600 mg on days 2 to 5 · infusion and intramuscular injectionAs given in this study (human).
Measurements
Treatment delay
55 weeks
GSH arm
Treatment delay
94 weeks
Placebo arm
Source sentences
Summary
In this trial, GSH also reduced hemotransfusion requirements (32 v 62 hemotransfusions) and treatment delay (55 v 94 weeks).
3 context sentences(design, population, supporting numbers)
Summary · context
Fifty patients with advanced gastric cancer treated with a weekly CDDP-based regimen were included in this study.
Summary · context
In patients randomized to receive GSH, GSH was given at a dose of 1.5 g/m2 in 100 mL of normal saline solution over a 15-minute period immediately before CDDP administration,
Summary · context
and at a dose of 600 mg by intramuscular injection on days 2 to 5.
Report a problemFND-0779902905
05HumanRandomized controlled trialEfficacy outcome
In patients with advanced gastric cancer, response was 76% with glutathione versus 52% with placebo.
In plain wordsIn patients with advanced gastric cancer, response was higher with glutathione than placebo.
Peptide
Glutathione
Outcome
IncreaseTumor response rate
Study
n = 50
Comparator
Placebo with cisplatin-based chemotherapy
Outcome group
Cancer treatment response · Cancer
Studied dose
1.5 g/m2 before CDDP and 600 mg on days 2 to 5 · infusion and intramuscular injectionAs given in this study (human).
Measurements
Tumor response rate
76%
GSH group
Tumor response rate
52%
Placebo arm
Source sentences
Summary
The response rate was 76% (20% complete response) in the GSH group and 52% (12% complete response) in the placebo arm, confirming preliminary reports about the lack of reduction in activity of cytotoxic drugs induced by GSH.
3 context sentences(design, population, supporting numbers)
Summary · context
Fifty patients with advanced gastric cancer treated with a weekly CDDP-based regimen were included in this study.
Summary · context
In patients randomized to receive GSH, GSH was given at a dose of 1.5 g/m2 in 100 mL of normal saline solution over a 15-minute period immediately before CDDP administration,
Summary · context
and at a dose of 600 mg by intramuscular injection on days 2 to 5.
Report a problemFND-0779902906
06HumanRandomized controlled trialEfficacy outcome
In patients with advanced gastric cancer, complete response was 20% with glutathione versus 12% with placebo.
In plain wordsIn patients with advanced gastric cancer, complete response was higher with glutathione than placebo.
Peptide
Glutathione
Outcome
IncreaseComplete tumor response
Study
n = 50
Comparator
Placebo with cisplatin-based chemotherapy
Outcome group
Cancer treatment response · Cancer
Studied dose
1.5 g/m2 before CDDP and 600 mg on days 2 to 5 · infusion and intramuscular injectionAs given in this study (human).
Measurements
Complete tumor response rate
20%
GSH group
Complete tumor response rate
12%
Placebo arm
Source sentences
Summary
The response rate was 76% (20% complete response) in the GSH group and 52% (12% complete response) in the placebo arm, confirming preliminary reports about the lack of reduction in activity of cytotoxic drugs induced by GSH.
3 context sentences(design, population, supporting numbers)
Summary · context
Fifty patients with advanced gastric cancer treated with a weekly CDDP-based regimen were included in this study.
Summary · context
In patients randomized to receive GSH, GSH was given at a dose of 1.5 g/m2 in 100 mL of normal saline solution over a 15-minute period immediately before CDDP administration,
Summary · context
and at a dose of 600 mg by intramuscular injection on days 2 to 5.
Report a problemFND-0779902907
07HumanRandomized controlled trialSafety outcome
In patients with advanced gastric cancer, neurotoxicity occurred in four of 24 glutathione patients versus 16 of 18 placebo patients.
In plain wordsIn patients with advanced gastric cancer, neurotoxicity occurred less often with glutathione than placebo after week 15.
Peptide
Glutathione
Outcome
DecreaseNeurotoxicity after week 15
Study
n = 42
Comparator
Placebo with cisplatin-based chemotherapy
Outcome group
Adverse events · Nervous system and cognition
Studied dose
1.5 g/m2 before CDDP and 600 mg on days 2 to 5 · infusion and intramuscular injection · 15 weeksAs given in this study (human).
Measurements
Patients with neurotoxicity
4 patients
GSH arm after week 15
Assessable patients
24 patients
GSH arm after week 15
Patients with neurotoxicity
16 patients
Placebo arm after week 15
Assessable patients
18 patients
Placebo arm after week 15
P value for neurotoxicity
0.0001
GSH versus placebo after week 15
Source sentences
Summary
After the 15th week, four of 24 assessable patients in the GSH arm suffered from neurotoxicity versus 16 of 18 in the placebo arm (P = .0001).
3 context sentences(design, population, supporting numbers)
Summary · context
Fifty patients with advanced gastric cancer treated with a weekly CDDP-based regimen were included in this study.
Summary · context
In patients randomized to receive GSH, GSH was given at a dose of 1.5 g/m2 in 100 mL of normal saline solution over a 15-minute period immediately before CDDP administration,
Summary · context
and at a dose of 600 mg by intramuscular injection on days 2 to 5.
Report a problemFND-0779902902

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.